Literature DB >> 12901348

Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia.

Marie-Claire Martyré1.   

Abstract

Myelofibrosis with myeloid metaplasia is an uncommon chronic myeloproliferative disorder characterized by extramedullary hematopoiesis associated with varying degrees of bone marrow fibrosis (hematopoiesis is clonal and fibrosis is a polyclonal reactive process). The primary defect in a pluripotent stem cell is still unknown. However, advances have been made during the past few years in the knowledge of the pathogenetic mechanisms in this disorder. This review focuses on current data on the cellular and molecular mechanisms possibly participating in the development of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901348

Source DB:  PubMed          Journal:  Curr Hematol Rep        ISSN: 1540-3408


  3 in total

1.  Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

Authors:  Talha Badar; Hagop M Kantarjian; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Jorge E Cortes; Naveen Pemmaraju; Sherry R Pierce; Kate J Newberry; Naval Daver; Srdan Verstovsek
Journal:  Leuk Res       Date:  2015-06-11       Impact factor: 3.156

2.  A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  A Quintás-Cardama; W Tong; H Kantarjian; D Thomas; F Ravandi; S Kornblau; T Manshouri; J E Cortes; G Garcia-Manero; S Verstovsek
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

Review 3.  The treatment of polycythaemia vera: an update in the JAK2 era.

Authors:  G Finazzi; T Barbui
Journal:  Intern Emerg Med       Date:  2007-03-31       Impact factor: 3.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.